Nobody expected the kind of vaccine sales as in 2009, and Diovan will have indirect generic competition.” Novartis plans to pay a dividend of 2.10 Swiss ...
The maker of blood pressure drug Diovan and anticancer drug Gleevec offered a positive outlook for 2010, predicting mid-to-high single digit growth in its ...
Exforge has been approved in Japan as a single-pill combination of two treatments for high blood pressure: Diovan® (valsartan), the number one selling ...